Pharmacists to help identify those who have yet to be vaccinated More than 370,000 people are either unvaccinated or only partially vaccinated
Israeli study claims Covid vaccine boosters reduce infection risk TENFOLD… day before FDA to decide on 3rd jab
A third dose of Pfizers vaccine could cut the risk of Covid infection by more than 10 times in elderly, according to a new Israeli study, which will be presented to the FDA amid heated debate over the need for universal boosters.
Published in the New England Journal of Medicine on Wednesday night, the newly peer-reviewed study found that infections and severe Covid cases “were substantially lower among those who received a booster (third) dose of the [Pfizer-BioNTech] vaccine” compared to those who took only two.
“The rate of confirmed infection was lower in the booster group than in the nonbooster group by a factor of 11.3,” the study said, also finding the rate of severe illness was slashed by nearly twentyfold, or by a factor of 19.5.
In study of participants in Israel who were 60+, the rates of confirmed #COVID19 & severe illness were substantially lower after a booster (third) dose of the BNT162b2 vaccine than after two doses. #SARSCoV2 #Covid19Vaccines #IDTwitter https://t.co/aOPyI7Y23s— NEJM (@NEJM) September 16, 2021
The findings are based on a review of official data for some 1.1 million Israelis over the age of 60, who were divided into two groups: those who received a booster within 5 months of their second dose, and those who did not.
Citing other recent research, the study noted that vaccine-induced immunity could drop significantly in just six months after a recipient’s second dose – providing only twice the protection compared to non-vaccinated individuals. After a third shot, however, effectiveness was pushed back up to 95%, “a value similar to the original vaccine efficacy reported against the alpha variant,” the study said.
While the researchers said they did their best to correct for any potential biases in the data, they acknowledged that their findings could reflect “behavioral changes after vaccination” rather than improved immunity alone, as the study did not attempt to measure antibody levels and instead relied on official case counts.
Nonetheless, the findings come as the US Food and Drug Administration (FDA) prepares to meet on Friday to decide on whether universal booster doses are needed for Americans. Dr. Sharon Alroy-Preis, one of the authors of the Israeli study, will present the new research at the meeting.